191 related articles for article (PubMed ID: 37492354)
1. THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM.
Gaćina K; Lešin M; Sarajčev D; Rotim N
Acta Clin Croat; 2022 Nov; 61(3):379-385. PubMed ID: 37492354
[TBL] [Abstract][Full Text] [Related]
2. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
[TBL] [Abstract][Full Text] [Related]
3. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
Wabbels B; Reichel G; Fulford-Smith A; Wright N; Roggenkämper P
J Neural Transm (Vienna); 2011 Feb; 118(2):233-9. PubMed ID: 21161715
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A therapy for blepharospasm.
Duarte GS; Rodrigues FB; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD004900. PubMed ID: 33211907
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
[TBL] [Abstract][Full Text] [Related]
9. Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm.
Tang M; Li W; Ji F; Li X; Zhang Y; Liu P
Psychol Health Med; 2019 Jun; 24(5):513-518. PubMed ID: 30463432
[TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
[TBL] [Abstract][Full Text] [Related]
11. Injecting botulinum toxin into the treatment of blepharospasm.
Popescu MN; Popescu SI; Cernat CC; Boariu AM; Călin E; Vieru A; Muşat O
Rom J Ophthalmol; 2018; 62(2):162-165. PubMed ID: 30206561
[TBL] [Abstract][Full Text] [Related]
12. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
[TBL] [Abstract][Full Text] [Related]
13. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
14. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
15. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A therapy for blepharospasm.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004900. PubMed ID: 15674969
[TBL] [Abstract][Full Text] [Related]
17. Relationship between various clinical outcome assessments in patients with blepharospasm.
Jankovic J; Kenney C; Grafe S; Goertelmeyer R; Comes G
Mov Disord; 2009 Feb; 24(3):407-13. PubMed ID: 19053054
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Injection Botulinum Toxin in Blepharospasm.
Amatya M; Limbu B; Sthapit PR; Gurung HB; Saiju R
Nepal J Ophthalmol; 2021 Jan; 13(25):40-49. PubMed ID: 33981096
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
